Filippo Pietrantonio, MD

home / authors / filippo-pietrantonio-md

Filippo Pietrantonio, MD, is a medical oncologist and head of the Gastrointestinal Oncology Unit at Fondazione IRCCS Istituto Nazionale dei Tumori.

Articles

Dr Pietrantonio on Amivantamab With/Without Chemotherapy in Right-Sided RAS/BRAF Wild-Type mCRC

Filippo Pietrantonio, MD

February 18th 2025

Filippo Pietrantonio, MD, discusses updated efficacy with amivantamab as monotherapy and in combination with chemotherapy in metastatic colorectal cancer.

Gathering Insights in Gastrointestinal Cancers From ESMO 2023: Dr Pietrantonio

Caroline Seymour;Filippo Pietrantonio, MD

October 22nd 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr Pietrantonio on the CodeBreak 300 Trial in KRAS G12C-mutated mCRC

Filippo Pietrantonio, MD

October 22nd 2023

Filippo Pietrantonio, MD, discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

Dr. Pietrantonio on Survival Rates in Colorectal Cancer

Filippo Pietrantonio, MD

January 14th 2017

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses survival rates in patients with colorectal cancer.

Dr. Pietrantonio on the Design and Rationale Behind a Nomogram to Predict Survival Rates in CRC

Filippo Pietrantonio, MD

October 18th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer.

Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

Filippo Pietrantonio, MD

August 11th 2016

Dr. Pietrantonio on Nomogram to Predict Survival Rates in CRC

Filippo Pietrantonio, MD

July 20th 2016

Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses findings of a clinical trial examining a nomogram used to predict 12-week survival rates for patients with colorectal cancer (CRC).